Original InvestigationAspirin Treatment and Outcomes After Percutaneous Coronary Intervention: Results of the ISAR-ASPI Registry
Under an Elsevier user license
open archive
Key Words
aspirin
biomarker
high platelet reactivity
stent thrombosis
Abbreviations and Acronyms
AA
arachidonic acid
ADP
adenosine diphosphate
AU
aggregation units
HAPR
high on-aspirin treatment platelet reactivity
HCPR
high on-clopidogrel treatment platelet reactivity
IDI
integrated discrimination improvement
MACE
major adverse cardiac event(s)
NRI
net reclassification improvement
NSTEMI
non–ST-segment elevation myocardial infarction
ST
stent thrombosis
STEMI
ST-segment elevation myocardial infarction
TIMI
Thrombolysis In Myocardial Infarction
Cited by (0)
Dr. Orban has received honoraria from Roche Diagnostics. Prof. Schunkert has received speaker fees from Sanofi-Aventis and Daiichi-Sankyo; and grants from Bristol-Myers Squibb. Prof. Kastrati has received lecture fees from Daiichi-Sankyo and AstraZeneca; and fees for advisory board activities from AstraZeneca. Dr. Sibbing has received speaker fees from Daiichi Sankyo and Roche; and fees for advisory board activities from Verum Diagnostica and Eli Lilly. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Copyright © 2014 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.